VVUS 3.05 Vivus Inc $VVUS Hit a 52 week low of 2.9
Post# of 38
Posted On: 11/19/2014 11:49:30 AM
VVUS 3.05 Vivus Inc $VVUS Hit a 52 week low of 2.97 Closing the day 10:44 at 3.05 +0.01 +0.33% With a day low of 2.97 and a total volume of 506,438.
VVUS Recent Posts: http://investorshangout.com/VIVUS-Inc-VVUS-55858/
VVUS Vivus Inc Recent Headline News
Why VIVUS (VVUS) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
VIVUS is well-equipped to bounce down the road with solid estimate revisions and an impressive Zacks Rank and looks well positioned for a solid gain
VVUS: 3.05 (+0.01)
Janssen Is Working Its Way Toward Anti-Obesity
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 4:14PM CST
ZFGN: 20.34 (-0.31), OREX: 5.56 (-0.06), NVO: 44.74 (+0.52), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
EnteroMedics May Enter The Obesity Space - What Does It Mean?
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 3:43PM CST
OREX: 5.56 (-0.06), ETRM: 1.31 (+0.01), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
For This Obesity Drug, Europe Trumps the U.S.
Brian Orelli, The Motley Fool - Motley Fool - Mon Nov 17, 3:00PM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave isn't off to the best start. As Chief Commercial Officer Mark Booth put it during the company's latest conference call: Unfortunately, like many new tactics, there have been some...
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.55 (-0.07), HLF: 38.59 (+0.27), NVO: 44.74 (+0.52), VVUS: 3.05 (+0.01), AMGN: 162.38 (+0.14), GSK: 46.22 (-0.06), ARNA: 4.14 (-0.17)
Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.22 (-0.04), VVUS: 3.05 (+0.01), CSIQ: 26.85 (-0.51), KING: 15.88 (-0.22), NVS: 95.59 (+0.01)
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), AMAG: 35.49 (+0.15)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.39 (-0.20), VVUS: 3.05 (+0.01), GSK: 46.22 (-0.06), ARNA: 4.14 (-0.17)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.05 (+0.01), SNY: 48.16 (-0.20), GNW: 9.24 (-0.12), REGN: 417.86 (+4.64)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.90 (+0.21), VVUS: 3.05 (+0.01), AMAG: 35.49 (+0.15), SNY: 48.16 (-0.20)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
VIVUS' (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 6:18PM CST
VVUS: 3.06 (+0.02)
Vivus tops Street 3Q forecasts
Automated Insights - Wed Nov 05, 4:45PM CST
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Wednesday reported a third-quarter loss of $15.8 million.
VVUS: 3.06 (+0.02)
Vivus Q3 revenues up 24%
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:29PM CST
VVUS: 3.06 (+0.02)
VVUS Recent Posts: http://investorshangout.com/VIVUS-Inc-VVUS-55858/
VVUS Vivus Inc Recent Headline News
Why VIVUS (VVUS) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
VIVUS is well-equipped to bounce down the road with solid estimate revisions and an impressive Zacks Rank and looks well positioned for a solid gain
VVUS: 3.05 (+0.01)
Janssen Is Working Its Way Toward Anti-Obesity
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 4:14PM CST
ZFGN: 20.34 (-0.31), OREX: 5.56 (-0.06), NVO: 44.74 (+0.52), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
EnteroMedics May Enter The Obesity Space - What Does It Mean?
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 3:43PM CST
OREX: 5.56 (-0.06), ETRM: 1.31 (+0.01), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
For This Obesity Drug, Europe Trumps the U.S.
Brian Orelli, The Motley Fool - Motley Fool - Mon Nov 17, 3:00PM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave isn't off to the best start. As Chief Commercial Officer Mark Booth put it during the company's latest conference call: Unfortunately, like many new tactics, there have been some...
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.55 (-0.07), HLF: 38.59 (+0.27), NVO: 44.74 (+0.52), VVUS: 3.05 (+0.01), AMGN: 162.38 (+0.14), GSK: 46.22 (-0.06), ARNA: 4.14 (-0.17)
Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.22 (-0.04), VVUS: 3.05 (+0.01), CSIQ: 26.85 (-0.51), KING: 15.88 (-0.22), NVS: 95.59 (+0.01)
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), AMAG: 35.49 (+0.15)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.39 (-0.20), VVUS: 3.05 (+0.01), GSK: 46.22 (-0.06), ARNA: 4.14 (-0.17)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.05 (+0.01), SNY: 48.16 (-0.20), GNW: 9.24 (-0.12), REGN: 417.86 (+4.64)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 32.90 (+0.21), VVUS: 3.05 (+0.01), AMAG: 35.49 (+0.15), SNY: 48.16 (-0.20)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.55 (-0.07), VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.05 (+0.01), ARNA: 4.14 (-0.17)
VIVUS' (VVUS) CEO Seth Fischer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 6:18PM CST
VVUS: 3.06 (+0.02)
Vivus tops Street 3Q forecasts
Automated Insights - Wed Nov 05, 4:45PM CST
MOUNTAIN VIEW, Calif. (AP) _ Vivus Inc. (VVUS) on Wednesday reported a third-quarter loss of $15.8 million.
VVUS: 3.06 (+0.02)
Vivus Q3 revenues up 24%
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:29PM CST
VVUS: 3.06 (+0.02)
(0)
(0)